To report or not to report: Exploring healthy volunteers' rationales for disclosing adverse events in Phase I drug trials

References

• Abadie, R. 2010. The professional guinea pig: Big pharma and the risky world of human subjects. Durham, NC: Duke University Press.
   Google Scholar
• Cottingham, M. D., and J. A. Fisher. 2016. Risk and emotion among healthy volunteers in clinical trials. Social Psychology Quarterly 79 (3):222–42. doi:10.1177/0190272516657655.
   PubMed Web of Science ®Google Scholar
• Czarny, M. J., N. E. Kass, C. Flexner, K. A. Carson, R. K. Myers, and E. J. Fuchs. 2010. Payment to healthy volunteers in clinical research: The research subject's perspective. Clinical Pharmacology & Therapeutics 87 (3):286–93. doi:10.1038/clpt.2009.222.
   PubMed Web of Science ®Google Scholar
• Devine, E. G, M. E. Waters, M. Putnam, C. Surprise, K. O'Malley, C. Richambault, R. L. Fishman, C. M. Knapp, E. H. Patterson, and O. Sarid-Segal. 2013. Concealment and fabrication by experienced research subjects. Clinical Trials 10:935–48. doi:10.1177/1740774513492917.
   PubMed Web of Science ®Google Scholar
• Dickert, N., E. Emanuel, and C. Grady. 2002. Paying research subjects: An analysis of current policies. Annals of Internal Medicine 136 (5):368–73. doi:10.7326/0003-4819-136-5-200203050-00009.
   PubMed Web of Science ®Google Scholar
• Dickert, N., and C. Grady. 1999. What's the price of a research subject? Approaches to payment for research participation. New England Journal of Medicine 341 (3):198–203. doi:10.1056/NEJM199907153410312.
   PubMed Web of Science ®Google Scholar
• Downing, N. S., N. D. Shah, J. A. Aminawung, A. M. Pease, J.-D. Zeitoun, H. M. Krumholz, and J. S. Ross. 2017. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 317 (18):1854–63. doi:10.1001/jama.2017.5150.
   PubMed Web of Science ®Google Scholar
• Dresser, R. 2013. Subversive subjects: Rule-breaking and deception in clinical trials. Journal of Law, Medicine and Ethics 41 (4):829–40. doi:10.1111/jlme.12093.
   PubMed Web of Science ®Google Scholar
• Edelblute, H. B., and J. A. Fisher. 2015. Using ‘Clinical Trial Diaries’ to track patterns of participation for serial healthy volunteers in U.S. Phase I Studies. Journal of Empirical Research on Human Research Ethics 10 (1):65–75. doi:10.1177/1556264614568280.
   PubMed Web of Science ®Google Scholar
• Edwards, I. R., and J. K. Aronson. 2000. Adverse drug reactions: Definitions, diagnosis, and management. The Lancet 356 (9237):1255–59. doi:10.1016/S0140-6736(00)02799-9.
   PubMed Web of Science ®Google Scholar
• Emanuel, E. J., G. Bedarida, K. Macci, N. B. Gabler, A. Rid, and D. Wendler. 2015. Quantifying the risks of non-oncology phase I research in healthy volunteers: Meta-analysis of phase I studies. British Medical Journal 350:h3271. doi:10.1136/bmj.h3271.
   PubMed Web of Science ®Google Scholar
• Fisher, J. A. 2015. Feeding and bleeding: The institutional banalization of risk to healthy volunteers in phase I pharmaceutical clinical trials. Science, Technology, & Human Values 40 (2):199–226. doi:10.1177/0162243914554838.
   PubMed Web of Science ®Google Scholar
• Fisher, J. A., and C. A. Kalbaugh. 2011. Challenging assumptions about minority participation in U.S. clinical research. American Journal of Public Health 101 (12):2217–22. doi:10.2105/AJPH.2011.300279.
   PubMed Web of Science ®Google Scholar
• Friedman, L. M., C. D. Furberg, and D. L. DeMets. 2010. Fundamentals of clinical trials. 4th ed. New York: Springer.
   Google Scholar
• Hermann, R., D. Heger-Mahn, M. Mahler, M. Seibert-Grafe, C. Klipping, K. Breithaupt-Grögler, and C. De Mey. 1997. Adverse events and discomfort in studies on healthy subjects: The volunteer's perspective. European Journal of Clinical Pharmacology 53 (3):207–14. doi:10.1007/s002280050364.
   PubMed Web of Science ®Google Scholar
• Iltis, A. S. 2009. Payments to normal healthy volunteers in phase 1 trials: Avoiding undue influence while distributing fairly the burdens of research participation. Journal of Medicine and Philosophy 34 (1):68–90. doi:10.1093/jmp/jhn036.
   PubMed Web of Science ®Google Scholar
• Ioannidis, J. P. A. 2009. Adverse events in randomized trials: Neglected, restricted, distorted, and silenced. Archives of internal medicine 169 (19):1737–39. doi:10.1001/archinternmed.2009.313.
   PubMedGoogle Scholar
• Ioannidis, J. P. A., S. J. W. Evans, P. C. Gøtzsche, R. T. O'Neill, D. G. Altman, K. Schulz, and D. Moher. 2004. Better reporting of harms in randomized trials: An extension of the CONSORT statement. Annals of internal medicine 141 (10):781–88. doi:10.7326/0003-4819-141-10-200411160-00009.
   PubMed Web of Science ®Google Scholar
• Johnson, R. A., A. Rid, E. Emanuel, and D. Wendler. 2016. Risks of phase I research with healthy participants: A systematic review. Clinical Trials 13 (2):149–60. doi:10.1177/1740774515602868.
   PubMed Web of Science ®Google Scholar
• Moore, T. J. 2015. Assessment and reporting of harm. In Fundamentals of clinical trials, 5th ed. eds. L. M. Friedman, C. D. Furberg, D. L. DeMets, D. M. Reboussin and C. B. Granger, 255–77. New York: Springer.
   Google Scholar
• Patton, M. Q. 2002. Qualitative research and evaluation methods. 3rd ed. Thousand Oaks, CA: Sage Publications.
   Google Scholar
• Resnik, D. B., and D. J. McCann. 2015. Deception by research participants. New England Journal of Medicine 373 (13):1192–93. doi:10.1056/NEJMp1506985.
   PubMed Web of Science ®Google Scholar
• Sibille, M., N. Deigat, A. Janin, S. Kirkesseli, and D. Vital Durand. 1998. Adverse events in phase-I studies: A report in 1015 healthy volunteers. European Journal of Clinical Pharmacology 54:13–20. doi:10.1007/s002280050413.
   PubMed Web of Science ®Google Scholar
• Sibille, M., Y. Donazzolo, F. Lecoz, and E. Krupka. 2006. After the London tragedy, is it still possible to consider Phase I is safe? British Journal of Clinical Pharmacology 62 (4):502–3. doi:10.1111/j.1365-2125.2006.02740.x.
   PubMed Web of Science ®Google Scholar
• Tavory, I., and S. Timmermans. 2014. Abductive analysis: Theorizing qualitative research. Chicago, IL: University of Chicago Press.
   Google Scholar
• Tishler, C. L., and S. Bartholomae. 2003. Repeat participation among normal healthy research volunteers: Professional guinea pigs in clinical trials? Perspectives in Biology and Medicine 46 (4):508–20. doi:10.1353/pbm.2003.0094.
   PubMed Web of Science ®Google Scholar